New EU Portal To Track Pricing & Reimbursement Applications
Move Will Help Uncover Root Causes Of Medicines Unavailability & Patient Access Delays
To improve patient access to approved drugs, European R&D-based companies have pledged to apply for pricing and reimbursement of drugs in all EU member states within two years of product approval. A new portal set up by EFPIA will track the progress of these applications, documenting reasons for pricing delays and barriers.
